Medical Specialty >> OncologyRead article
- As Mammograms Became Widespread, Breast Tumor Size Shrank
- Breast Symptoms at Mammogram May Raise Future Cancer Risk
- Could a Pap Test Spot More Than Just Cervical Cancer?
- Task Force Issues Stronger Skin Cancer Prevention Guidelines
- Lean Approach May Help Tackle Burnout in Health Care Providers
- History of Cancer Tied to Lower Endurance, Higher Fatigability
- Nivolumab Plus Ipilimumab Tops Sunitinib for Advanced Renal CA
Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of… Elizabeth M. Swisher, MD. Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity… Bert Vogelstein, MD. Investigators at Johns Hopkins University in Baltimore used complex mathematical modeling to track mutations driving abnormal cell growth for 32 types of cancer. From their calculations, the researchers believe that the bulk of cancers are caused by random DNA copying errors (replicative mutations).…
Great articles. learnt a lot from it.